PRODUCT INFORMATION



OSS-128167

Item No. 29052

CAS Registry No.:	887686-02-4	
Formal Name:	5-[[3-[(2-furanylcarbonyl)amino]	
	benzoyl]amino]-2-hydroxy-benzoic acid	
MF:	$C_{19}H_{14}N_2O_6$ O	
FW:		
Purity:	≥98%	1
UV/Vis.:	λ_{max} : 216, 238, 279 nm	
Supplied as:	A crystalline solid	
Storage:	-20°C	
Stability:	≥4 years	
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.		

Laboratory Procedures

OSS-128167 is supplied as a crystalline solid. A stock solution may be made by dissolving the OSS-128167 in the solvent of choice, which should be purged with an inert gas. OSS-128167 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of OSS-128167 in these solvents is approximately 30 mg/ml.

OSS-128167 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, OSS-128167 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. OSS-128167 has a solubility of approximately 0.12 mg/ml in a 1:7 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

OSS-128167 is an inhibitor of sirtuin 6 (SIRT6; IC₅₀ = 89 μ M).¹ It is selective for SIRT6 over SIRT1 and SIRT2 (IC₅₀s = 1,578 and 751 μ M, respectively). OSS-128167 increases acetylation of histone H3 lysine 9 (H3K9) and glucose uptake and decreases TNF- α release in BxPC-3 cells. In vivo, OSS-128167 (100 μg/animal, i.c.v.) prevents decreases in left hemisphere cerebral levels of IL-1β, TNF-α, and IL-6 and neutrophil infiltration induced by bexarotene (Item No. 11571) in a rat model of subarachnoid hemorrhage.²

References

- 1. Damonte, P., Sociali, G., Parenti, M.D., et al. SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. Bioorg. Med. Chem. 25(20), 5849-5858 (2017).
- 2. Zuo, Y., Huang, L., Enkhjargal, B., et al. Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARy/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats. J. Neuroinflammation 16(1):47, (2019).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM